Cargando…
Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price
INTRODUCTION: An estimated 6 million Americans have Alzheimer's disease (AD). Aducanumab was recently approved by the Food and Drug Administration despite the lack of clinical effectiveness data. METHODS: We developed a Markov state transition model of AD to estimate the cost effectiveness of a...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900580/ https://www.ncbi.nlm.nih.gov/pubmed/35282659 http://dx.doi.org/10.1002/trc2.12256 |